Omicron And Acquisitions Push Up Galenica's Swiss OTC Sales By A Third
Executive Summary
Galenica's Verfora substantially outpaced the 6.4% growth rate of the Swiss consumer health market in the first half, posting sales up by a third thanks to a combination of acquisitions and increased demand for cold & flu products due to the spread of the COVID-19 Omicron variant.